Antithrombotic Management After Intracranial Hemorrhage
| Autor: | Destiny Hooper, Christian E. Cajavilca, Rajeel Imran, Rajan R Gadhia |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Secondary prevention
medicine.medical_specialty Vascular disease business.industry MEDLINE 030204 cardiovascular system & hematology medicine.disease 03 medical and health sciences 0302 clinical medicine Ischemic stroke Antithrombotic medicine In patient cardiovascular diseases 030212 general & internal medicine Acute management Risk factor management Cardiology and Cardiovascular Medicine business Intensive care medicine |
| Zdroj: | Current Treatment Options in Cardiovascular Medicine. 21 |
| ISSN: | 1534-3189 1092-8464 |
| DOI: | 10.1007/s11936-019-0771-y |
| Popis: | Intracranial hemorrhage remains one of the most feared acute neurological emergencies. However, apart from the acute management, secondary risk factor management and prevention of ischemic events remains ambiguous. We present a thorough review of the current data available regarding management of antithrombotics after intracranial hemorrhage. The most robust evidence comes from the investigators of the RESTART trial which reassured the safety of resuming antiplatelet therapy after ICH, namely in patients with prior indication and treatment with antithrombotics. We conclude that based on available data, the risk of recurrent ICH is probably too small to exceed the found benefits of antiplatelet therapy in the secondary prevention of ischemic vascular disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink